10 March 2011
Ovarian cancer survival rates in England and Wales have doubled in the past 30 years, according to new figures released by Cancer Research UK.
The organisation claims that more than two in five women diagnosed with the condition now survive - compared to just a fifth of diagnosed patients who survived a generation earlier.
As a result, an additional 1,000 women a year are surviving ovarian cancer for at least five years.
However, Cancer Research UK claimed that early diagnosis was still the key to treatment as late-stage cases were still dangerous.
Dr James Brenton, who is based at Cancer Research UK's Cambridge Research Institute, said: "These latest figures show improvements in treatment, such as centralisation of ovarian cancer surgery and uniform access to chemotherapy, are making a difference."
"But we face a real challenge in translating these improvements in survival to women whose ovarian cancer has already spread," he added.
Recently, Professor Charis Eng, chair of the Genomic Medicine Institute of Cleveland Clinic's Lerner Research Institute, claimed that chemotherapy response could be boosted by reservatol - a compound commonly found in red wines.
1 "CancerStats Key Facts Ovarian Cancer". Cancer Research UK. March 2011.
2 Eng, Charis. "Red wine compound increases anti-tumor effect of rapamycin". Cancer Letters. Monday, February 14th 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.